Resolve Therapeutics

Resolve Therapeutics is a United States-based biopharmaceutical company focused on the discovery and development of innovative non-immunosuppressive biologics for autoimmune diseases. According to its official website, the company's pipeline centers on RSLV-132, an investigational biologic being developed for lupus, Sjögren's syndrome, and Long COVID. The company positions its approach around modulating the immune system without broadly suppressing it, a strategy intended to address autoimmune pathology while potentially avoiding the infection and malignancy risks associated with conventional immunosuppressive therapies. Resolve Therapeutics is associated with St. Petersburg, in the US state of Florida, according to Wikidata and seed reference data. The company operates as a privately held, clinical-stage biopharmaceutical developer rather than a commercial-stage manufacturer, meaning its primary activities are research, preclinical and clinical development, and regulatory strategy for its investigational product candidates. Its lead program, RSLV-132, is described by the company as a biologic for autoimmune indications. The named target indications — lupus, Sjögren's syndrome, and Long COVID — represent conditions in which chronic immune dysregulation plays a central role and where existing treatment options often rely on immunosuppression with significant side-effect burdens. By pursuing a non-immunosuppressive mechanism, Resolve Therapeutics aims to differentiate its candidate in these areas. As a small, privately held developer, Resolve Therapeutics does not disclose extensive public financial or operational details. Its public presence is primarily through its corporate website, which serves as the main source of information about its pipeline and therapeutic focus. The company's activities are concentrated in the United States, and its development programs target both autoimmune and post-viral inflammatory conditions.

Resolve Therapeutics is a privately held biopharmaceutical company based in the United States, associated with St. Petersburg, Florida. The company was established to develop biologic therapies that modulate the immune system without causing broad immunosuppression, a therapeutic strategy aimed at treating autoimmune diseases more safely than conventional immunosuppressive treatments. The company's public profile is centered on its lead investigational candidate, RSLV-132. According to the company's official website, RSLV-132 is being developed for lupus, Sjögren's syndrome, and Long COVID. These indications share an underlying component of immune dysregulation, and the company's non-immunosuppressive approach is intended to address that dysregulation while potentially reducing the risk of opportunistic infections and other complications associated with immunosuppressive drugs. As a clinical-stage developer, Resolve Therapeutics focuses on research and development, including preclinical studies and clinical trials, rather than on marketed products. Detailed corporate history, including exact founding dates, funding rounds, and leadership, is not widely documented in the public sources available. The company maintains a corporate website at resolvetherapeutics.com as its primary public communications channel. Resolve Therapeutics operates within the broader US biotechnology sector, specifically the autoimmune and inflammatory disease therapeutic area. Its activities are concentrated in the United States, and its pipeline targets conditions with significant unmet medical need.

Clinical-stage biopharmaceutical developer of non-immunosuppressive biologics for autoimmune diseases.

• RSLV-132

  Investigational non-immunosuppressive biologic being developed for lupus, Sjögren's syndrome, and Long COVID.

1. 1Resolve Therapeutics | Biopharma for Autoimmune Diseaseresolvetherapeutics.com
2. 2Resolve Therapeutics (United States) - Wikidatawikidata.org